Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on April 22, 2020. The registrant is a Delaware corporation with its principal executive offices in San Diego, CA. The report addresses corporate governance changes rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a Current Report (Form 8-K) focused on a specific event and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the election of three new independent Directors to the Board of Directors on April 22, 2020:
- Dr. James Armitage
- Ms. Lâle White
- Dr. Gary Pace
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The sole purpose of this report is to disclose the board composition change via a press release furnished as Exhibit 99.1.
Investor Verification Checklist
- Verify the biographies and qualifications of the three newly elected directors (Dr. Armitage, Ms. White, Dr. Pace).
- Confirm the total size of the Board of Directors following these elections.
- Review the full text of the press release (Exhibit 99.1) for any additional context on the board's strategic direction.
- Note that this filing does not contain financial data; refer to the most recent 10-Q or 10-K for financial metrics.